zuranolone Zurzuvae oral
Selected indexed studies
- Zuranolone for the Treatment of Postpartum Depression. (Am J Psychiatry, 2023) [PMID:37491938]
- The Black Book of Psychotropic Dosing and Monitoring. (Psychopharmacol Bull, 2024) [PMID:38993656]
- Zuranolone (Zurzuvae) - An oral drug for postpartum depression. (Med Lett Drugs Ther, 2023) [PMID:38133592]
_Worker-drafted node — pending editorial review._
Connections
zuranolone Zurzuvae oral is a side effect of
Sources
- The Black Book of Psychotropic Dosing and Monitoring. (2024) pubmed
- Zuranolone for the Treatment of Postpartum Depression. (2023) pubmed
- Zuranolone: First Approval. (2023) pubmed
- Zuranolone for the Treatment of Adults With Major Depressive Disorder: A Randomized, Placebo-Controlled Phase 3 Trial. (2023) pubmed
- Preclinical characterization of zuranolone (SAGE-217), a selective neuroactive steroid GABA(A) receptor positive allosteric modulator. (2020) pubmed
- Zuranolone: The First FDA-Approved Oral Treatment Option for Postpartum Depression. (2024) pubmed
- Zuranolone (Zurzuvae) - An oral drug for postpartum depression. (2023) pubmed
- Screening and the New Treatment for Postpartum Depression. (2023) pubmed
- Zuranolone: A Narrative Review of a New Oral Treatment for Postpartum Depression. (2024) pubmed
- Brexanolone, zuranolone and related neurosteroid GABA(A) receptor positive allosteric modulators for postnatal depression. (2025) pubmed